<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859207</url>
  </required_header>
  <id_info>
    <org_study_id>E2609-A001-103</org_study_id>
    <nct_id>NCT02859207</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects</brief_title>
  <official_title>An Open-Label Parallel-Group Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effects of hepatic impairment on the&#xD;
      pharmacokinetics (PK) of E2609 after a single dose administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">January 25, 2017</completion_date>
  <primary_completion_date type="Actual">December 6, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for pharmacokinetic (PK) assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under plasma concentration versus time curve from time zero to time of last quantifiable concentration (AUC(0-t)) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under plasma concentration versus time curve from time zero to infinity (AUC(0-inf)) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time to reach maximum plasma concentration (tmax) of E2609 and its metabolites</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean terminal phase plasma half-life (t1/2) of E2609 and its metabolites</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent total body clearance (CL/F) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent volume of distribution (Vz/F) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ratio of AUC(0-inf) of individual metabolite to AUC(0-inf) of E2609, corrected for molecular weight (AUC metabolite ratio)</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean plasma protein unbound fraction (fu) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cmax values adjusted for unbound fraction in plasma (Cmaxu) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC(0-inf) values adjusted by unbound fraction in plasma (AUCu) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Apparent clearance relative to the unbound plasma concentration based on AUCu (CLu/F) of E2609</measure>
    <time_frame>Day 1 through 7</time_frame>
    <description>Blood samples for PK assessments will be collected on Day 1 (before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing), Day 2 (24 and 36 hours after dosing), Day 3 (48 hours after dosing), Day 4 (72 hours after dosing), Day 5 (96 hours after dosing), Day 6 (120 hours after dosing), and Day 7 (144 hours after dosing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events and serious adverse events</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Early Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment (Child-Pugh class A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants (control) matched to participants in Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (Child-Pugh class B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants (control) matched to participants in Cohort 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2609</intervention_name>
    <description>Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 2C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Nonsmoking, male or female, ≥18 years and ≤70 years of age at the time of informed&#xD;
             consent, and with body mass index (BMI) of up to 40 kg/m2, inclusive.&#xD;
&#xD;
          2. For Cohorts 1 and 2: stable mild or moderate hepatic impairment conforming to&#xD;
             Child-Pugh class A or B, respectively, documented by medical history, physical&#xD;
             examination and 1 or more of the following diagnostic procedures documented in the&#xD;
             medical notes: liver biopsy, computed tomography (CT) scan, magnetic resonance imaging&#xD;
             (MRI), ultrasound, radionuclide liver/spleen scan, or abdominal laparoscopy.&#xD;
             Participants whose liver imaging was done more than 1 year ago or previous results&#xD;
             were not available, should have a liver ultrasound scan to ensure that the liver&#xD;
             structure is consistent with the diagnosis of hepatic impairment and that there are no&#xD;
             exclusionary features.&#xD;
&#xD;
          3. For Cohorts 1C and 2C: healthy participants matched to participants with mild or&#xD;
             moderate hepatic impairment with regard to age (±10 years), body weight (±20%), and&#xD;
             gender; and as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, electrocardiogram (ECG), and clinical&#xD;
             laboratory determinations.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        For all Participants (Cohorts 1, 2, 1C, and 2C)&#xD;
&#xD;
          1. Females participants who are breastfeeding or pregnant at Screening or Baseline (as&#xD;
             documented by a positive beta-human chorionic gonadotropin [ß-hCG] test. A separate&#xD;
             baseline assessment is required if a negative screening pregnancy test was obtained&#xD;
             more than 72 hours before the dose of study drug.&#xD;
&#xD;
          2. Females of childbearing potential who:&#xD;
&#xD;
               -  Had unprotected sexual intercourse within 30 days before study entry and who do&#xD;
                  not agree to use a highly effective method of contraception (eg, total&#xD;
                  abstinence, an intrauterine device, a double-barrier method [such as condom plus&#xD;
                  diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or&#xD;
                  have a vasectomized partner with confirmed azoospermia) throughout the entire&#xD;
                  study period or for 28 days after study drug discontinuation.&#xD;
&#xD;
               -  Are currently abstinent and do not agree to use a double-barrier method (as&#xD;
                  previously described) or refrain from sexual activity during the study period or&#xD;
                  for 28 days after study drug discontinuation .&#xD;
&#xD;
               -  Are using hormonal contraceptives but are not on a stable dose of the same&#xD;
                  hormonal contraceptive product except those containing estradiol for at least 4&#xD;
                  weeks before dosing and who do not agree to use the same contraceptive during the&#xD;
                  study or for 28 days after study drug discontinuation.&#xD;
&#xD;
               -  Are using estradiol-containing hormonal contraceptives within 4 weeks before&#xD;
                  dosing (NOTE: All females will be considered to be of childbearing potential&#xD;
                  unless they are postmenopausal [amenorrheic for at least 12 consecutive months,&#xD;
                  in the appropriate age group, and without other known or suspected cause] or have&#xD;
                  been sterilized surgically [eg, bilateral tubal ligation, total hysterectomy, or&#xD;
                  bilateral oophorectomy; all with surgery at least 1 month before dosing]).&#xD;
&#xD;
          3. Males who have not had a successful vasectomy (unconfirmed azoospermia) or they and&#xD;
             their female partners do not meet the criteria specified in exclusion criterion 2 (eg,&#xD;
             unwilling to refrain from sexual activity, not of childbearing potential or practicing&#xD;
             highly effective contraception throughout the study period or for 28 days after study&#xD;
             drug discontinuation).&#xD;
&#xD;
          4. Inability to tolerate oral medication.&#xD;
&#xD;
          5. Inability to be venipunctured and/or tolerate venous access. For Hepatically Impaired&#xD;
             Participants (Cohorts 1 and 2)&#xD;
&#xD;
          6. Any significant acute medical illness (such as new conditions or exacerbation or&#xD;
             pre-existing conditions) within 4 weeks before dosing.&#xD;
&#xD;
          7. Medical conditions which are not adequately and stably controlled on stable doses of&#xD;
             medications or which, in the clinical opinion of the investigator, may interfere with&#xD;
             study procedures or participant safety within 4 weeks before dosing; eg, psychiatric&#xD;
             disorders and disorders of the gastrointestinal tract, kidney, respiratory system,&#xD;
             endocrine system, hematological system, neurological system, or cardiovascular system,&#xD;
             or participants who have a congenital abnormality in metabolism. Participants with&#xD;
             history of seizures during adulthood are excluded. Participants with a history of&#xD;
             Gilbert's syndrome are excluded.&#xD;
&#xD;
          8. History of esophageal and gastric variceal bleeding within the past 3 months unless&#xD;
             the participant has completed a course of endoscopic therapy with the appropriate&#xD;
             documentation (eg, endoscopy report) of successful ablation of esophageal varices;&#xD;
             participants with esophageal varices may be included if not bleeding within the past 3&#xD;
             months or have been treated adequately by ablation therapy.&#xD;
&#xD;
          9. Spontaneous bacterial peritonitis within 3 months before dosing.&#xD;
&#xD;
         10. Treatment with plasmapheresis within 6 months before dosing.&#xD;
&#xD;
         11. Primarily cholestatic liver diseases (eg, primary biliary cirrhosis or primary&#xD;
             sclerosing cholangitis).&#xD;
&#xD;
         12. Current or recent (within 3 months before Screening) history of significant&#xD;
             gastrointestinal disease other than that secondary to hepatic impairment.&#xD;
&#xD;
         13. Autoimmune liver disease.&#xD;
&#xD;
         14. Active alcoholic hepatitis determined either clinically or by histology per the&#xD;
             discretion of the investigator.&#xD;
&#xD;
         15. History of hepatoma or metastatic disease of the liver.&#xD;
&#xD;
         16. Presence of severe ascites or edema.&#xD;
&#xD;
         17. Presence of hepatopulmonary syndrome or hydrothorax, or hepatorenal syndrome.&#xD;
&#xD;
         18. Known significant bleeding diathesis that could preclude multiple venipunctures&#xD;
             (International Normalized Ratio [INR] &gt;2.5).&#xD;
&#xD;
         19. Any major surgery within 4 weeks before dosing.&#xD;
&#xD;
         20. Any history of abdominal surgery that may affect the pharmacokinetic (PK) of E2609&#xD;
             (eg, hepatectomy, nephrectomy, digestive organ resection, transjugular intrahepatic&#xD;
             portosystemic shunt [TIPS]) at Screening or Baseline (history of cholecystectomy need&#xD;
             not be exclusionary).&#xD;
&#xD;
         21. Donation of blood or plasma within 4 weeks before dosing.&#xD;
&#xD;
         22. Receipt of blood or blood products within 4 weeks before dosing.&#xD;
&#xD;
         23. Known to be human immunodeficiency virus (HIV)-positive at Screening.&#xD;
&#xD;
         24. Creatinine clearance &lt;60 mL/min at Screening or Baseline, as calculated using Cockroft&#xD;
             and Gault equation.&#xD;
&#xD;
         25. Known history of clinically significant drug allergy at Screening.&#xD;
&#xD;
         26. Known history of food allergies or presently experiencing significant seasonal or&#xD;
             perennial allergy at Screening.&#xD;
&#xD;
         27. History of drug or alcohol dependency or abuse within 4 weeks before Screening, or&#xD;
             those who have a positive urine drug test or breath (or urine) alcohol test at&#xD;
             Screening or Baseline unless a prescribed medication for the underlying condition is&#xD;
             the cause of the positive urine screen.&#xD;
&#xD;
         28. A prolonged QT/QTc interval (QTc Fridericia [QTcF] &gt;480 ms) demonstrated on the ECG at&#xD;
             Screening or Baseline. A history of risk factors for torsade de pointes (eg, heart&#xD;
             failure, hypokalemia, family history of long QT Syndrome).&#xD;
&#xD;
         29. Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 28 days or 5× the half-life of the investigational drug, whichever is&#xD;
             longer, preceding informed consent.&#xD;
&#xD;
         30. Intake of nutritional supplements, juice, and herbal preparations or other foods or&#xD;
             beverages that may affect the various drug metabolizing enzymes and transporters (eg,&#xD;
             alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or&#xD;
             orange juice, vegetables from the mustard green family [eg, kale, broccoli,&#xD;
             watercress, collard greens, kohlrabi, brussel sprouts, mustard], and charbroiled&#xD;
             meats) within 1 week before dosing.&#xD;
&#xD;
         31. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing&#xD;
             .&#xD;
&#xD;
         32. Engagement in strenuous exercise within 2 weeks before Baseline.&#xD;
&#xD;
             For Healthy Participants (Cohorts 1C and 2C)&#xD;
&#xD;
         33. Clinically significant illness that requires medical treatment within 8 weeks or a&#xD;
             clinically significant infection that requires medical treatment within 4 weeks of&#xD;
             dosing.&#xD;
&#xD;
         34. Evidence of disease that may influence the outcome of the study within 4 weeks before&#xD;
             dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver,&#xD;
             kidney, respiratory system, endocrine system, hematological system, neurological&#xD;
             system, or cardiovascular system), or participants who have a congenital abnormality&#xD;
             in metabolism. Participants with history of seizures in adulthood are excluded.&#xD;
&#xD;
         35. Any history of gastrointestinal surgery that may affect the drug absorption (eg,&#xD;
             hepatectomy, nephrotomy, digestive organ resection, but not cholecystectomy) at&#xD;
             Screening.&#xD;
&#xD;
         36. Any clinically abnormal symptom or organ impairment found by medical history at&#xD;
             Screening, and physical examinations, vital sign assessments, ECG finding, or&#xD;
             laboratory test results that require medical treatment at Screening.&#xD;
&#xD;
         37. A prolonged QT/QTc interval (QTcF &gt;450 ms) demonstrated on ECG at Screening or&#xD;
             Baseline. A history of risk factors for torsade de pointes (eg, heart failure,&#xD;
             hypokalemia, family history of long QT Syndrome), or the use of concomitant&#xD;
             medications that prolonged the QT/QTc interval.&#xD;
&#xD;
         38. Known history of clinically significant drug allergy at Screening.&#xD;
&#xD;
         39. Known history of food allergies or presently experiencing significant seasonal or&#xD;
             perennial allergy at Screening.&#xD;
&#xD;
         40. Known to be HIV-positive at Screening.&#xD;
&#xD;
         41. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening.&#xD;
&#xD;
         42. History of drug or alcohol dependency or abuse within the 1 year before Screening, or&#xD;
             those who have a positive urine drug test or breath (or urine) alcohol test at&#xD;
             Screening or Baseline.&#xD;
&#xD;
         43. Intake of nutritional supplements, juice, and herbal preparations or other foods or&#xD;
             beverages that may affect the various drug metabolizing enzymes and transporters (eg,&#xD;
             alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or&#xD;
             orange juice, vegetables from the mustard green family [eg, kale, broccoli,&#xD;
             watercress, collard greens, kohlrabi, brussel sprouts, mustard], and charbroiled&#xD;
             meats) within 1 week before dosing.&#xD;
&#xD;
         44. Intake of herbal preparations containing St. John's wort within 4 weeks before dosing.&#xD;
&#xD;
         45. Use of prescription drugs except those allowed per the inclusion/exclusion criteria&#xD;
             (eg, contraception) within 4 weeks or 5 half-lives, whichever is longer, before&#xD;
             dosing.&#xD;
&#xD;
         46. Intake of over-the-counter (OTC) medications within 2 weeks or 5 half-lives, whichever&#xD;
             is longer, before dosing.&#xD;
&#xD;
         47. Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 28 days or 5x the half-life of the investigational drug, whichever is&#xD;
             longer, preceding informed consent.&#xD;
&#xD;
         48. Receipt of blood or blood products within 4 weeks, or donation of blood within 4&#xD;
             weeks, of dosing.&#xD;
&#xD;
         49. Engagement in strenuous exercise within 2 weeks before Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Alzheimer's disease</keyword>
  <keyword>E2609</keyword>
  <keyword>Mild and Moderate Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

